About Jason Haas
Jason Haas is a director at Ligand Pharmaceuticals.
Form D filings name Jason Haas as CFO at Odyssey Therapeutics.
Jason Haas reports to the SEC as a director or officer of 3 public companies, including Odyssey Therapeutics (ODTX) and Syros Pharmaceuticals (SYRS).
Jason Haas first appears on SEC filings in 2021.
Experience
This experience comes from SEC filings. The years are when the filings name Jason Haas in the role, so the role may have started earlier or lasted longer.
LI
Ligand Pharmaceuticals Inc.
Director
2022 – 2026 · Public company (LGND)
SI
Syros Pharmaceuticals, Inc.
Chief Financial Officer
2021 – 2024 · Public company (SYRS)
Key Colleagues at Startups
The people Jason Haas works with at each company, as listed on that company's latest Form D.
Odyssey Therapeutics, Inc. · Form D, Dec 4, 2025
VO
Valerie Odegard
Director
CG
Carl Gordon
Director
CN
Carolyn Ng
Director
GG
Gary Glick
President & CEO, director
TW
Timothy Walbert
Director
Paulina Hill
Director
NL
Nan Li
Director
JL
Jeffrey Leiden
Director
NT
Nia Tatsis
Director
KP
Ksenija Pavletic
Director
SC
Shelley Chu
Director
LS
Lan Smith
Director
JC
Jill Carroll
Director